A previous retrospective analysis from the STS/ACC TVT registry (15) showed how treatment with ACEIs/ARBs during hospital discharge in TAVI patients was related to a decreased risk of mortality and hospitalization for heart failure within 1 year, while more recent basic science findings showed an increased benefit of ARBs compared with ACEIs, probably due to their effect on the valve chymase and their ability to block the escape mechanism of RAAS induced by ACEIs (16, 17). Here, CMA1 is linked to heart failure.